There may not be a safe off-ramp for some taking GLP-1 drugs, study suggests

The popularity of GLP-1 weight-loss medications continues to soar—and their uptake is helping to push down obesity rates on a national scale—but a safe, evidence-based way off the drugs isn’t yet in clear view.

An analysis published this week in JAMA Internal Medicine found that most participants in a clinical trial who were assigned to stop taking tirzepatide (Zepbound from Eli Lilly) not only regained significant amounts of the weight they had lost on the drug, but they also saw their cardiovascular and metabolic improvements slip away. Their blood pressure went back up, as did their cholesterol, hemoglobin A_1c (used to assess glucose control levels), and fasting insulin.

In an accompanying editorial, two medical experts at the University of Pittsburgh, Elizabeth Oczypok and Timothy Anderson, suggest that this new class of drugs should be rebranded from “weight loss” drugs to “weight management” drugs, which people may ...